The Effect of Surface-Modified Gold Nanorods on the Early Stage of Embryonic Development and Angiogenesis: Insight into the Molecular Pathways.
Animals
Apoptosis
/ drug effects
Chick Embryo
Chickens
Chorioallantoic Membrane
/ blood supply
Embryonic Development
/ drug effects
Gold
/ chemistry
Nanotubes
/ chemistry
Neovascularization, Physiologic
/ drug effects
Polyethylene Glycols
/ chemistry
Signal Transduction
/ drug effects
Surface Properties
Transcription Factor RelA
/ metabolism
angiogenesis
apoptosis
chick chorioallantoic membrane
embryogenesis
gold nanorods
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Oct 2021
13 Oct 2021
Historique:
received:
31
08
2021
revised:
24
09
2021
accepted:
30
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Gold nanorods have been implicated in several biomedical applications. Herein, the effect of two surface-modified gold nanorods on the early stages of embryogenesis and angiogenesis was investigated using avian embryos at three days and their chorioallantoic membrane (CAM) at five days of incubation. We found that gold nanorods (GNR) modified with PEGylated phospholipid moiety show a high mortality rate in embryos after four days of exposure compared to GNR modified with PEGylated cholesterol moiety. Meanwhile, our data revealed that surface modified-GNR significantly inhibit the formation of new blood vessels in the treated CAM model after 48 h of exposure. Moreover, we report that surface-modified GNR significantly deregulate the expression of several genes implicated in cell proliferation, invasion, apoptosis, cellular energy metabolism, and angiogenesis. On the other hand, our data point out that GNR treatments can modulate the expression patterns of JNK1/2/3, NF-KB/p38, and MAPK, which could be the main molecular pathways of the nanorods in our experimental models.
Identifiants
pubmed: 34681694
pii: ijms222011036
doi: 10.3390/ijms222011036
pmc: PMC8537453
pii:
doi:
Substances chimiques
Transcription Factor RelA
0
Polyethylene Glycols
3WJQ0SDW1A
Gold
7440-57-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Al-Zaytoonah University of Jordan
ID : 2020-2019/12/28
Références
PLoS One. 2015 May 06;10(5):e0126176
pubmed: 25946186
Biostat Bioinforma Biomath. 2013 Aug;3(3):71-85
pubmed: 25558171
Genes Cells. 2005 Mar;10(3):253-60
pubmed: 15743414
J Exp Clin Cancer Res. 2018 Oct 30;37(1):263
pubmed: 30376856
Chem Pharm Bull (Tokyo). 2017;65(7):625-628
pubmed: 28674334
Mol Pharm. 2019 Oct 7;16(10):4149-4164
pubmed: 31398052
J Mol Cell Cardiol. 2015 Jan;78:107-15
pubmed: 25264175
Sci Rep. 2017 Jun 19;7(1):3827
pubmed: 28630477
Biomed Pharmacother. 2021 Feb;134:111134
pubmed: 33341672
Oncogene. 2012 Mar 15;31(11):1389-97
pubmed: 21804602
Oncogene. 2008 Oct 20;27(48):6245-51
pubmed: 18931691
Int J Clin Exp Pathol. 2015 Aug 01;8(8):9264-71
pubmed: 26464675
Cell Microbiol. 2004 Feb;6(2):187-99
pubmed: 14706104
Nano Lett. 2013 Feb 13;13(2):765-71
pubmed: 23286198
J Clin Med. 2019 Dec 29;9(1):
pubmed: 31905724
Reprod Toxicol. 2017 Jun;70:97-101
pubmed: 27832950
Cell. 2011 Sep 16;146(6):873-87
pubmed: 21925313
Int J Clin Exp Med. 2015 Jun 15;8(6):8369-76
pubmed: 26309490
Future Sci OA. 2018 Jun 28;4(7):FSO318
pubmed: 30112188
Biomolecules. 2021 Feb 27;11(3):
pubmed: 33673519
Sci Rep. 2019 Apr 8;9(1):5796
pubmed: 30962476
Cell Death Differ. 2011 Dec;18(12):1889-903
pubmed: 21660047
Adv Drug Deliv Rev. 2012 Feb;64(2):190-9
pubmed: 21397647
EMBO Mol Med. 2015 Oct 12;7(11):1418-25
pubmed: 26459520
Nat Med. 2000 Apr;6(4):389-95
pubmed: 10742145
Clin Cancer Res. 2005 May 1;11(9):3530-4
pubmed: 15867256
Breast Cancer Res Treat. 2015 Sep;153(2):465-74
pubmed: 26298189
Cancer Res. 2000 Aug 1;60(15):4085-92
pubmed: 10945614
Exp Ther Med. 2018 Jul;16(1):133-140
pubmed: 29896233
J Exp Clin Cancer Res. 2011 Sep 26;30:87
pubmed: 21943236
Cell Death Differ. 2006 May;13(5):759-72
pubmed: 16410803
Tumour Biol. 2017 Jul;39(7):1010428317708547
pubmed: 28714365
Curr Med Chem. 2019;26(35):6493-6513
pubmed: 31057102
Chem Sci. 2020 Jan 15;11(4):923-936
pubmed: 34084347
Biochim Biophys Acta. 2014 Aug;1846(1):161-79
pubmed: 24836679
Small. 2021 Jul;17(27):e2004381
pubmed: 33511773
Oncol Lett. 2018 Sep;16(3):3083-3091
pubmed: 30127899
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4390-5
pubmed: 19251665
Oncologist. 2015 Jun;20(6):660-73
pubmed: 26001391
Transl Oncol. 2019 Jul;12(7):981-986
pubmed: 31121490
ACS Omega. 2021 Jun 11;6(24):15903-15910
pubmed: 34179634
Adv Exp Med Biol. 2009;647:186-94
pubmed: 19760075
Oncogene. 2008 Sep 25;27(43):5696-705
pubmed: 18542057
Nature. 2001 Mar 1;410(6824):37-40
pubmed: 11242034
Vasc Cell. 2011 Jan 31;3(1):3
pubmed: 21349160
J Biomed Nanotechnol. 2020 Jun 1;16(6):975-984
pubmed: 33187592
Int J Nanomedicine. 2016 Jun 07;11:2633-9
pubmed: 27354794
Cancer. 1993 Aug 1;72(3):783-7
pubmed: 8392905
Dis Model Mech. 2016 Feb;9(2):105-14
pubmed: 26839398
Cell Prolif. 2016 Dec;49(6):678-697
pubmed: 27641938
Biomed Pharmacother. 2018 Sep;105:440-448
pubmed: 29879628
Front Cell Infect Microbiol. 2018 Apr 04;8:105
pubmed: 29670864
Cell Physiol Biochem. 2015;37(6):2323-38
pubmed: 26645893
Front Bioeng Biotechnol. 2018 Feb 12;6:7
pubmed: 29484295
Oncotarget. 2014 Sep 30;5(18):8569-82
pubmed: 25149542
Mol Med Rep. 2015 Sep;12(3):4314-4319
pubmed: 26059756
Immunotherapy. 2018 Sep;10(13):1175-1188
pubmed: 30236026
Small. 2018 Oct;14(42):e1801451
pubmed: 30239120
PLoS One. 2011;6(11):e27385
pubmed: 22110636
Int J Nanomedicine. 2017 May 04;12:3509-3520
pubmed: 28496326
Int J Nanomedicine. 2019 Sep 19;14:7643-7663
pubmed: 31571869
Cancer Lett. 2013 Aug 28;337(1):66-76
pubmed: 23693077
Dev Growth Differ. 2007 Feb;49(2):163-70
pubmed: 17335437
Acta Oncol. 2006;45(4):375-88
pubmed: 16760173
Mol Cancer. 2019 May 23;18(1):100
pubmed: 31122251